abrdn Life Sciences - Public Comps and Valuation Multiples

abrdn Life Sciences Overview

About abrdn Life Sciences

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.

Founded

1992

HQ

Employees

n/a

Website

abrdnhql.com

Sectors

Asset Management

Financials

Last FY Revenue $86.4M

Last FY EBITDA n/a

EV

$497M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

abrdn Life Sciences Financials

See abrdn Life Sciences valuation multiples based on analyst estimates

abrdn Life Sciences P&L

In the most recent fiscal year, abrdn Life Sciences reported revenue of $86.4M.

abrdn Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

See abrdn Life Sciences valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$86.4M	XXX	XXX	XXX
Gross Profit	XXX	n/a	XXX	XXX	XXX
Gross Margin	XXX	n/a	XXX	XXX	XXX
EBITDA	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	XXX	n/a	XXX	XXX	XXX
EBIT	XXX	n/a	XXX	XXX	XXX
EBIT Margin	XXX	n/a	XXX	XXX	XXX
Net Profit	XXX	$85.6M	XXX	XXX	XXX
Net Margin	XXX	99%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for abrdn Life Sciences including revenue, profitability, and margin analysis across different time periods.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$86.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	NaN% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$85.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	99.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for abrdn Life Sciences

This financial data table provides comprehensive performance metrics for abrdn Life Sciences, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, abrdn Life Sciences reported $86.4M in total revenue.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was NaN%.
Net profit margin reached 99.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for abrdn Life Sciences. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

abrdn Life Sciences Stock Performance

abrdn Life Sciences has current market cap of $497M, and EV of $497M.

Market Cap Evolution

abrdn Life Sciences Stock Data

As of December 10, 2025, abrdn Life Sciences's stock price is $17.

See abrdn Life Sciences trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$497M	$497M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

abrdn Life Sciences Valuation Multiples

abrdn Life Sciences's trades at 5.8x EV/Revenue multiple, and n/a EV/EBITDA.

See valuation multiples for abrdn Life Sciences and 15K+ public comps

abrdn Life Sciences Financial Valuation Multiples

As of December 10, 2025, abrdn Life Sciences has market cap of $497M and EV of $497M.

Equity research analysts estimate abrdn Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

abrdn Life Sciences's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$497M	XXX	$497M	XXX	XXX	XXX
EV (current)	$497M	XXX	$497M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	5.8x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	n/a	XXX	XXX	XXX
EV/EBIT	n/a	XXX	n/a	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	5.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	15.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get abrdn Life Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

abrdn Life Sciences Margins & Growth Rates

abrdn Life Sciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

abrdn Life Sciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

abrdn Life Sciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for abrdn Life Sciences and other 15K+ public comps

abrdn Life Sciences Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	1%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial